To further explore a possible early risk of infection (Figure 1a), the rates of serious infections were analyzed with followup censored at 90 days after the start of anti-TNFα therapy (or 90 days after registration date in the DMARD cohort) (Table 3). The gene discussed is TNF; the disease is infection.